Compare Blackrock Inc (BLK) vs DexCom, Inc. (DXCM) Price & Performance

BlackRock (BLK) trades at $1,031.56, down 0.44% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results anticipated. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. The company maintains robust profitability metrics, including a 24.4% net income margin and 11.95% ROE. Recent news highlights the launch of a new Nasdaq-100 ETF, IQQ, challenging Invesco's QQQ.

The outlook for BLK remains positive, driven by earnings momentum, strategic ETF expansion, and solid institutional support. Key risks include market volatility affecting asset management fees and competitive pressures in the ETF space. With 76% of analysts rating it a Buy and a consensus price target of $1,290, the stock presents a compelling opportunity for growth-oriented investors, though monitoring Q2 earnings and macroeconomic trends is essential.

DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.

DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.